PREDECT Protocols for Complex 2D/3D Cultures.


Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2019
Historique:
entrez: 7 12 2018
pubmed: 7 12 2018
medline: 5 6 2019
Statut: ppublish

Résumé

PREDECT, a European IMI consortium, has assumed the task to generate robust 2D and 3D culture platforms. Protocols established for 2D and 3D monoculture and stromal coculture models of increasing complexity (spheroid, stirred-tank bioreactor, Matrigel- and collagen-embedded cultures) have been established between six laboratories within academia, biotech, and pharma. These models were tested using three tumor cell lines (MCF7, LNCaP, and NCI-H1437), covering three pathologies (breast, prostate, and lung), but should be readily transferable to other model systems. Fluorescent protein tagged cell lines were used for all platforms, allowing for online measurement of growth curves and drug responses to treatments. All methods, from culture setup to phenotypic characterization and gene expression profiling are described in this chapter.The adaptable methodologies and detailed protocols described here should help to include these models more readily to the drug discovery pipeline.

Identifiants

pubmed: 30519938
doi: 10.1007/978-1-4939-8891-4_1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-20

Auteurs

Suzana Vidic (S)

Faculty of Medicine, Institute of Biochemistry, University of Ljubljana, Ljubljana, Slovenia.

Marta F Estrada (MF)

iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

Kjersti Gjerde (K)

Janssen Pharmaceutica N.V, Beerse, Belgium.

Vítor E Santo (VE)

iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

Annika Osswald (A)

Boehringer Ingelheim RCV, GmbH & Co. KG, Vienna, Austria.

Michaël Barbier (M)

Laboratory of Cell Biology and Histology, Department of Veterinary Sciences, University of Antwerp, Wilrijk, Belgium.

Yolanda T Chong (YT)

Recursion Pharmaceuticals, Salt Lake City, UT, USA.

Wolfgang Sommergruber (W)

Boehringer Ingelheim RCV, GmbH & Co. KG, Vienna, Austria.

Ronald de Hoogt (R)

Janssen Pharmaceutica N.V, Beerse, Belgium.

Catarina Brito (C)

iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

Ralph Graeser (R)

Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany. r.graeser17@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH